IRadimed Corp (IRMD) News & EventsIRMDIRadimed Corp

Company Expects Q4 2026 Revenue of $25M to $26.5M

Sees Q4 revenue $25M-$26.5M, consensus $26.23M. The company said, "For the fourth quarter of 2026, the Company expects revenue of $25.0 million to $26.5 million, GAAP diluted earnings per share of $0.53 to $0.57, and non-GAAP diluted earnings per share of $0.57 to $0.61."

Iradimed Reports Q3 Revenue of $24.2M

Reports Q3 revenue $24.2M, consensus $23.43M. "We are pleased to report record revenue of $24.2 million for the third quarter, driven by the continued successful launch of our new 3870 MR IV pump. As our manufacturing team gains experience with the new platform while at the same time greatly ramping up production, we began realizing the efficiencies we anticipated with gross margin improving sequentially as expected. Quarterly bookings also set new records, driven by another record number of monitor units being booked and a 45% year-over-year increase in domestic pump channels booked. Of special note is that over 70% of pump bookings in the quarter were for our 'quad stack' configuration of four pumps on a single IV pole, as customers continue to accelerate their replacement of our older model and standardize on this setup which is a doubling of pump channels previously available at each MRI. With record bookings and rapidly building 3870 momentum, we believe we are well positioned for a strong finish to the year," said Roger Susi, President and Chief Executive Officer of Iradimed.

Company Narrows FY26 Revenue Outlook to $91.6M-$93.1M

Consensus $2.11. Narrows FY26 revenue view to $91.6M-$93.1M from $91M-$96M, consensus $92.07M. The company said, "For the full year 2026, the Company expects to report revenue of $91.6 million to $93.1 million, GAAP diluted earnings per share of $1.90 to $1.94, and non-GAAP diluted earnings per share of $2.07 to $2.11."